機関投資家の保有一覧

ADAR1 Capital Management, LLC

持ち方

—

評価額を取得中

届出上位5銘柄の比重

—

保有

244銘柄

ADAR1 Capital Management, LLC は、2026年6月30日の SEC Form 13F で 244 銘柄の保有を報告しました。届出上位には Abivax、Protagonist Therapeutics、Roivant Sciences が並び、ヘルスケアにまたがります。下の銘柄名と保有株数は届出に基づきます。

届出上位の10銘柄

1
AB
ABVXAbivax
ヘルスケア・ 1,804,703 株
—
2
PT
PTGXProtagonist Therapeutics
ヘルスケア・ 960,863 株
—
3
RO
ROIVRoivant Sciences
ヘルスケア・ 3,157,008 株
—
4
SP
SPYSPDR S&P 500 ETF TRUST
—・ 129,087 株
—
5
ZL
ZLABZai Lab
ヘルスケア・ 3,369,034 株
—
6
IM
IMVTImmunovant
ヘルスケア・ 2,330,716 株
—
7
AG
AGIOAgios Pharmaceuticals
ヘルスケア・ 1,288,053 株
—
8
SE
SEPNSepterna
ヘルスケア・ 940,747 株
—
9
CY
CYTKCytokinetics
ヘルスケア・ 457,907 株
—
10
VI
VIRVir Biotechnology
ヘルスケア・ 2,456,677 株
—

残り 234 銘柄をすべて見る ▾

#	銘柄	保有株数	概算評価額
11	SYRESpyre Therapeutics	283,982	—
12	INSPInspire Medical Systems	374,617	—
13	INSMInsmed	228,520	—
14	AVRAnteris Technologies	3,145,096	—
15	EDITEditas Medicine	8,889,000	—
16	PRAXPraxis Precision Medicines	74,253	—
17	DNLIDenali Therapeutics	1,029,080	—
18	CLDXCelldex Therapeutics	619,542	—
19	ELVNEnliven Therapeutics	387,718	—
20	RVMDRevolution Medicines	87,509	—
21	OVIDOvid Therapeutics	7,417,479	—
22	ENTAEnanta Pharmaceuticals	1,344,510	—
23	VKTXViking Therapeutics	574,038	—
24	MNPRMonopar Therapeutics	217,595	—
25	REGNRegeneron Pharmaceuticals	22,208	—
26	RLYBRallybio	926,352	—
27	ANLAdlai Nortye	1,017,805	—
28	IKTInhibikase Therapeutics	7,387,205	—
29	TSHATaysha Gene Therapies	3,040,466	—
30	AMLXAmylyx Pharmaceuticals	494,378	—
31	PRTAProthena	1,554,535	—
32	IVAInventiva	3,606,656	—
33	SRPTSarepta Therapeutics	730,649	—
34	VORVor Biopharma	680,626	—
35	RYTMRhythm Pharmaceuticals	136,158	—
36	ESTAEstablishment Labs	185,619	—
37	BBIOBridgeBio Pharma	176,689	—
38	TEVATeva Pharmaceutical	277,848	—
39	NKTRNektar Therapeutics	244,184	—
40	HLXCHelix Acquisition Corp. III	1,000,000	—
41	URGNUroGen Pharma	252,395	—
42	FTHFaeth Therapeutics	361,010	—
43	CLYMClimb Bio	822,649	—
44	MAZEMaze Therapeutics	339,276	—
45	CTMXCytomX Therapeutics	3,365,118	—
46	REPLReplimune Group	655,784	—
47	PCVXVaxcyte	146,034	—
48	IRDOpus Genetics	1,783,781	—
49	CGONCG Oncology	118,664	—
50	AMANAmanat Acquisition Corp.	750,000	—
51	QUREuniQure	324,672	—
52	IONSIonis Pharmaceuticals	166,286	—
53	ZURAZura Bio	1,759,295	—
54	NRIXNurix Therapeutics	313,236	—
55	JANXJanux Therapeutics	420,881	—
56	MLYSMineralys Therapeutics	298,886	—
57	PFEPfizer	252,400	—
58	RACCResearch Alliance Corp III	650,000	—
59	RLAYRelay Therapeutics	358,333	—
60	SVRASavara	1,403,409	—
61	ASNDAscendis Pharma	28,604	—
62	BHVNBiohaven	501,687	—
63	XENEXenon Pharmaceuticals	166,550	—
64	STROSutro Biopharma	404,014	—
65	PRMEPrime Medicine	1,997,552	—
66	EWTXEdgewise Therapeutics	143,199	—
67	PEPGPepGen	2,591,085	—
68	DMRADamora Bio	280,000	—
69	XNCRXencor	232,560	—
70	FULCFulcrum Therapeutics	1,565,029	—
71	OKUROnKure Therapeutics	2,238,684	—
72	PLRXPliant Therapeutics	5,509,724	—
73	ABUSArbutus Biopharma	1,268,147	—
74	DBVTDBV Technologies	528,295	—
75	DHRDanaher	25,932	—
76	LXEOLexeo Therapeutics	1,565,950	—
77	EQEquillium	3,758,569	—
78	GMEDGlobus Medical	70,100	—
79	KRYSKrystal Biotech	16,420	—
80	ALECAlector	2,883,583	—
81	KRROKorro Bio	540,054	—
82	IFRXInflaRx	3,000,000	—
83	BOLDBoundless Bio	1,968,216	—
84	WHWKWhiteHawk Therapeutics	1,341,394	—
85	BHFBrighthouse Financial	95,523	—
86	OABIOmniAb	947,412	—
87	JATTJATT II Acquisition Corp.	417,724	—
88	ARWRArrowhead Pharmaceuticals	69,800	—
89	ABOSAcumen Pharmaceuticals	2,111,334	—
90	ONCBeOne Medicines	11,701	—
91	AVLNAvalyn Pharma	146,447	—
92	ENGNenGene Holdings	2,104,986	—
93	SGMTSagimet Biosciences	437,500	—
94	BIIBBiogen	17,900	—
95	LONALeonaBio	777,100	—
96	CTNMContineum Therapeutics	278,961	—
97	SLNSilence Therapeutics	338,373	—
98	RNTXRein Therapeutics	4,500,000	—
99	DCTHDelcath Systems	224,385	—
100	CATXPerspective Therapeutics	1,210,117	—
101	PRLDPrelude Therapeutics	900,900	—
102	PHVSPharvaris	105,528	—
103	SMMTSummit Therapeutics	191,869	—
104	IVVDInvivyd	3,807,427	—
105	SPRBSpruce Biosciences	67,717	—
106	KROSKeros Therapeutics	246,818	—
107	BMRNBioMarin Pharmaceutical	49,000	—
108	NAMSNewAmsterdam Pharma	118,623	—
109	CRBPCorbus Pharmaceuticals	421,787	—
110	TARAProtara Therapeutics	940,512	—
111	INOInovio Pharmaceuticals	2,143,910	—
112	PALIPalisade Bio	1,726,662	—
113	SPRYARS Pharmaceuticals	600,999	—
114	TRAXFirst Tracks Biotherapeutics	71,910	—
115	ISRGIntuitive Surgical	6,030	—
116	AEXAAmerican Exceptionalism Acquisition Corp. A	205,408	—
117	SNYSanofi	57,100	—
118	GOSSGossamer Bio	212,531	—
119	GLUEMonte Rosa Therapeutics	216,752	—
120	MCKMcKesson	2,500	—
121	IOVAIovance Biotherapeutics	146,090	—
122	KNSAKiniksa Pharmaceuticals International	26,913	—
123	AVTRAvantor	130,000	—
124	MSLESatellos Bioscience	222,555	—
125	TNGXTango Therapeutics	76,761	—
126	ORKAOruka Therapeutics	20,840	—
127	ZNTLZentalis Pharmaceuticals	652,750	—
128	RLMDRelmada Therapeutics	451,918	—
129	ELDNEledon Pharmaceuticals	647,812	—
130	DRUGBright Minds Biosciences	30,300	—
131	CUECue Biopharma	55,193	—
132	LXRXLexicon Pharmaceuticals	750,000	—
133	CRVSCorvus Pharmaceuticals	117,101	—
134	SUPNSupernus Pharmaceuticals	27,842	—
135	RCKTRocket Pharmaceuticals	435,500	—
136	BCRXBioCryst Pharmaceuticals	133,000	—
137	INMInMed Pharmaceuticals	800,000	—
138	BNTXBioNTech	10,600	—
139	NVONovo Nordisk	27,000	—
140	HELPCybin	81,278	—
141	AREAlexandria Real Estate Equities	19,500	—
142	NTRANatera	2,147	—
143	PMNProMIS Neurosciences	92,850	—
144	TNYATenaya Therapeutics	1,555,500	—
145	CCCCC4 Therapeutics	291,957	—
146	SIBNSI-BONE	45,000	—
147	CAPRCapricor Therapeutics	90,593	—
148	ARTVArtiva Biotherapeutics	118,624	—
149	LRMRLarimar Therapeutics	272,745	—
150	AURAAura Biosciences	130,152	—
151	ACADACADIA Pharmaceuticals	38,955	—
152	FWRDForward Air	48,241	—
153	IDYAIDEAYA Biosciences	20,000	—
154	LUNGPulmonx	404,497	—
155	RNACCartesian Therapeutics	98,877	—
156	EVMNEvommune	104,035	—
157	RPRXRoyalty Pharma	12,500	—
158	EOLSEvolus	100,000	—
159	TXMDTherapeuticsMD	342,447	—
160	GILDGilead Sciences	4,648	—
161	ALXOALX Oncology Holdings	533,660	—
162	CNTBConnect Biopharma	700,000	—
163	DYNDyne Therapeutics	42,821	—
164	GERNGeron Corporation	505,817	—
165	WVEWave Life Sciences	160,000	—
166	CCXIChurchill Capital Corp XI	50,000	—
167	VSTMVerastem	75,800	—
168	KZIAKazia Therapeutics	61,550	—
169	VERAVera Therapeutics	18,322	—
170	KIDSOrthoPediatrics	25,000	—
171	SYKStryker	2,000	—
172	PYPDPolyPid	103,950	—
173	GPCRStructure Therapeutics	17,500	—
174	SPTXSeaport Therapeutics	26,000	—
175	MGNXMacroGenics	129,822	—
176	ASMBAssembly Biosciences	20,447	—
177	MRKMerck	3,140	—
178	RNAAtrium Therapeutics	57,688	—
179	MDGLMadrigal Pharmaceuticals	895	—
180	TENXTenax Therapeutics	220,462	—
181	ARVNArvinas	57,591	—
182	KURAKura Oncology	40,000	—
183	IBIOiBio	375,531	—
184	ACHVAchieve Life Sciences	53,800	—
185	BABAAlibaba Group	3,578	—
186	COGTCogent Biosciences	12,200	—
187	CNSPCNS Pharmaceuticals	70,000	—
188	PMVPPMV Pharmaceuticals	201,008	—
189	BNTCBenitec Biopharma	40,000	—
190	TRAWTraws Pharma	597,729	—
191	ANTXAN2 Therapeutics	58,808	—
192	IRTCiRhythm Holdings	3,000	—
193	TECXTectonic Therapeutic	14,501	—
194	MIRMMirum Pharmaceuticals	3,900	—
195	BSXBoston Scientific	7,500	—
196	WWWW International	21,300	—
197	MLTXMoonLake Immunotherapeutics	27,000	—
198	PHATPhathom Pharmaceuticals	42,900	—
199	ALTAltimmune	102,823	—
200	LGVNLongeveron	108,406	—
201	KLRSKalaris Therapeutics	100,000	—
202	CBIOCrescent Biopharma	18,275	—
203	DERMJourney Medical	39,517	—
204	MPLTMapLight Therapeutics	26,497	—
205	JDJD.com	10,000	—
206	SCYXSCYNEXIS	49,387	—
207	PSNLPersonalis	15,000	—
208	BCAXBicara Therapeutics	13,705	—
209	RXSTRxSight	50,000	—
210	CNTXContext Therapeutics	750,969	—
211	STIMNeuronetics	100,000	—
212	CEPSCantor Equity Partners VI, Inc.	20,000	—
213	NGNENeurogene	7,800	—
214	COYACoya Therapeutics	40,900	—
215	RZLTRezolute	48,679	—
216	ADGMAdagio Medical	1,205,447	—
217	ANABAnaptysBio	3,698	—
218	BCYCBicycle Therapeutics	50,638	—
219	RXRXRecursion Pharmaceuticals	41,000	—
220	OGNOrganon	10,000	—
221	CMMBChemomab Therapeutics	80,000	—
222	CMPXCompass Therapeutics	122,132	—
223	NMRANeumora Therapeutics	210,000	—
224	NEUPNeuphoria Therapeutics	30,000	—
225	CAESCantor Equity Partners VII, Inc.	10,000	—
226	CABACabaletta Bio	50,000	—
227	VTGNVistagen Therapeutics	351,141	—
228	LITSLite Strategy, Inc.	67,292	—
229	VERUVeru	35,000	—
230	VYGRVoyager Therapeutics	35,000	—
231	TRDAEntrada Therapeutics	15,500	—
232	MISTMilestone Pharmaceuticals	100,000	—
233	JSPRJasper Therapeutics	140,000	—
234	CLNNClene	15,000	—
235	BMEABiomea Fusion	43,420	—
236	QCLSQ/C Technologies	50,000	—
237	ARDXArdelyx	11,000	—
238	PRQRProQR Therapeutics	10,000	—
239	ATYRaTyr Pharma	50,685	—
240	CHRSCoherus BioSciences	10,366	—
241	CRNXCRNX	1,222,080	—
242	ATAIATAI	913,242	—
243	CYCNCYCN	298,757	—
244	APGEAPGE	31,000	—

2026年6月30日時点の SEC への Form 13F 届出 (運用資産 $100M 以上の機関投資家が四半期ごとに提出) の集計。届出は四半期末から最大45日遅れで公開されるため、現在の保有と異なる場合があります。概算評価額と構成比は当サイトの株価で計算した参考値です。届出対象外の資産 (米国外上場株・債券など) は含まれません。